Buccolam

Maa: Euroopan unioni

Kieli: englanti

Lähde: EMA (European Medicines Agency)

Osta se nyt

Pakkausseloste Pakkausseloste (PIL)
08-02-2024
Valmisteyhteenveto Valmisteyhteenveto (SPC)
08-02-2024

Aktiivinen ainesosa:

midazolam

Saatavilla:

Neuraxpharm Pharmaceuticals S.L.

ATC-koodi:

N05CD08

INN (Kansainvälinen yleisnimi):

midazolam

Terapeuttinen ryhmä:

Psycholeptics

Terapeuttinen alue:

Epilepsy

Käyttöaiheet:

Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from three months to less than 18 years).Buccolam must only be used by parents / carers where the patient has been diagnosed to have epilepsy.For infants between three and six months of age, treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.

Tuoteyhteenveto:

Revision: 18

Valtuutuksen tilan:

Authorised

Valtuutus päivämäärä:

2011-09-04

Pakkausseloste

                                52
B. PACKAGE LEAFLET
53
PACKAGE LEAFLET: INFORMATION FOR THE USER
BUCCOLAM 2.5 MG OROMUCOSAL SOLUTION
FOR CHILDREN AGED 3 MONTHS TO LESS THAN 1 YEAR
BUCCOLAM 5 MG OROMUCOSAL SOLUTION
FOR CHILDREN AGED 1 YEAR TO LESS THAN 5 YEARS
BUCCOLAM 7.5 MG OROMUCOSAL SOLUTION
FOR CHILDREN AGED 5 YEARS TO LESS THAN 10 YEARS
BUCCOLAM 10 MG OROMUCOSAL SOLUTION
FOR CHILDREN AGED 10 YEARS TO LESS THAN 18 YEARS
Midazolam
READ ALL OF THIS LEAFLET CAREFULLY, BEFORE YOU START GIVING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for your child. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as those of the child for
whom this medicine has been
prescribed.
•
If you see any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What BUCCOLAM is and what it is used for
2.
What you need to know before you give BUCCOLAM
3.
How to give BUCCOLAM
4.
Possible side effects
5.
How to store BUCCOLAM
6.
Contents of the pack and other information
1.
WHAT BUCCOLAM IS AND WHAT IT IS USED FOR
BUCCOLAM contains a medicine called midazolam. Midazolam belongs to a
group of medicines
known as benzodiazepines. BUCCOLAM is used to stop a sudden,
prolonged, convulsive, seizure in
infants, toddlers, children and adolescents (from 3 months to less
than 18 years of age).
In infants from 3 months to less than 6 months it should only be used
in a hospital setting where
monitoring is possible and resuscitation equipment is available.
This medicine must only be used by parents/carers where the child has
been diagnosed to have
epilepsy.
2.
WHAT YOU NEED TO KNOW BEFORE YOU GIVE BUCCOLAM
DO NOT GIVE BUCCOLAM IF THE PATIENT HAS:
•
An allergy to midazolam, benzodiazepines (such as diazepam) or any of
the other ingredients of
this medicine (l
                                
                                Lue koko asiakirja
                                
                            

Valmisteyhteenveto

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
BUCCOLAM 2.5 mg oromucosal solution
BUCCOLAM 5 mg oromucosal solution
BUCCOLAM 7.5 mg oromucosal solution
BUCCOLAM 10 mg oromucosal solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
BUCCOLAM 2.5 mg oromucosal solution
Each pre-filled oral syringe contains 2.5 mg midazolam (as
hydrochloride) in 0.5 ml solution
BUCCOLAM 5 mg oromucosal solution
Each pre-filled oral syringe contains 5 mg midazolam (as
hydrochloride) in 1 ml solution
BUCCOLAM 7.5 mg oromucosal solution
Each pre-filled oral syringe contains 7.5 mg midazolam (as
hydrochloride) in 1.5 ml solution
BUCCOLAM 10 mg oromucosal solution
Each pre-filled oral syringe contains 10 mg midazolam (as
hydrochloride) in 2 ml solution
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oromucosal solution
Clear colourless solution
pH 2.9 to 3.7
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of prolonged, acute, convulsive seizures in infants,
toddlers, children and adolescents (from
3 months to < 18 years).
BUCCOLAM must only be used by parents/carers where the patient has
been diagnosed to have
epilepsy.
For infants between 3-6 months of age treatment should be in a
hospital setting where monitoring is
possible and resuscitation equipment is available. See section 4.2.
3
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Standard doses are indicated below:
AGE RANGE
DOSE
LABEL COLOUR
3
_ _
to 6 months hospital
setting
2.5 mg
Yellow
> 6 months to < 1 year
2.5 mg
Yellow
1 year to < 5 years
5 mg
Blue
5 years to < 10 years
7.5 mg
Purple
10 years to < 18 years
10 mg
Orange
Carers should only administer a single dose of midazolam. If the
seizure has not stopped within 10
minutes after administration of midazolam, emergency medical
assistance must be sought and the
empty syringe given to the healthcare professional to provide
information on the dose received by the
patient.
A second or repeat dose when seizures re-occur after an initial
response should not b
                                
                                Lue koko asiakirja
                                
                            

Asiakirjat muilla kielillä

Pakkausseloste Pakkausseloste bulgaria 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto bulgaria 08-02-2024
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta bulgaria 19-09-2011
Pakkausseloste Pakkausseloste espanja 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto espanja 08-02-2024
Pakkausseloste Pakkausseloste tšekki 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto tšekki 08-02-2024
Pakkausseloste Pakkausseloste tanska 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto tanska 08-02-2024
Pakkausseloste Pakkausseloste saksa 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto saksa 08-02-2024
Pakkausseloste Pakkausseloste viro 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto viro 08-02-2024
Pakkausseloste Pakkausseloste kreikka 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto kreikka 08-02-2024
Pakkausseloste Pakkausseloste ranska 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto ranska 08-02-2024
Pakkausseloste Pakkausseloste italia 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto italia 08-02-2024
Pakkausseloste Pakkausseloste latvia 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto latvia 08-02-2024
Pakkausseloste Pakkausseloste liettua 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto liettua 08-02-2024
Pakkausseloste Pakkausseloste unkari 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto unkari 08-02-2024
Pakkausseloste Pakkausseloste malta 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto malta 08-02-2024
Pakkausseloste Pakkausseloste hollanti 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto hollanti 08-02-2024
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta hollanti 19-09-2011
Pakkausseloste Pakkausseloste puola 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto puola 08-02-2024
Pakkausseloste Pakkausseloste portugali 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto portugali 08-02-2024
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta portugali 19-09-2011
Pakkausseloste Pakkausseloste romania 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto romania 08-02-2024
Pakkausseloste Pakkausseloste slovakki 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto slovakki 08-02-2024
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta slovakki 19-09-2011
Pakkausseloste Pakkausseloste sloveeni 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto sloveeni 08-02-2024
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta sloveeni 19-09-2011
Pakkausseloste Pakkausseloste suomi 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto suomi 08-02-2024
Pakkausseloste Pakkausseloste ruotsi 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto ruotsi 08-02-2024
Pakkausseloste Pakkausseloste norja 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto norja 08-02-2024
Pakkausseloste Pakkausseloste islanti 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto islanti 08-02-2024
Pakkausseloste Pakkausseloste kroatia 08-02-2024
Valmisteyhteenveto Valmisteyhteenveto kroatia 08-02-2024

Etsi tähän tuotteeseen liittyviä ilmoituksia

Näytä asiakirjojen historia